Literature DB >> 31833559

Therapeutic effects of an azaphenothiazine derivative in mouse experimental colitis.

Jolanta Artym1, Maja Kocięba1, Ewa Zaczyńska1, Michał Zimecki2, Wojciech Kałas1, Leon Strządała1, Alicja Pawlak1, Małgorzata Jeleń3, Beata Morak-Młodawska3, Krystian Pluta3, Katarzyna Kaleta-Kuratewicz4, Jan P Madej4, Piotr Kuropka4, Jan Kuryszko4.   

Abstract

Phenothiazines represent a class of compounds of potential therapeutic utility. In this report we evaluated therapeutic value of an azaphenothiazine derivative, 6-acetylaminobutyl-9-chloroquino[3,2-b]benzo[1,4]thiazine (QBT), given intragastrically, in the model of dextran sodium sulfate-induced colitis in C57BL/6 mice using 5-aminosalicylic acid (5-ASA) as a reference drug. Colitis symptoms such as body weight loss, diarrhea and hematochezia (blood in stool) were observed and registered and disease activity index (DAI) was calculated. In addition, weight and cell numbers in the lymphatic organs and histological parameters of the colon wall were analyzed. The effects of QBT on viability of colon epithelial cell lines were also determined. We showed that weight and cell number of draining mesenteric lymph nodes were lower in mice treated with QBT in comparison to their control counterparts. The number of thymocytes, drastically reduced in control mice, was elevated in mice treated with the compounds with a significant effect of 5-ASA. In addition, an abnormal composition of blood cell types was partially corrected in these groups. Histological analysis of the colon revealed that the pathological changes were partially normalized by QBT and even to a higher degree by 5-ASA. In conclusion we demonstrated a therapeutic efficacy of the compound in amelioration of local and systemic pathological changes associated with chemically-induced colitis in mice. A possible mechanism of action of the compound is discussed.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31833559     DOI: 10.14670/HH-18-192

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  29 in total

Review 1.  Novel therapeutic targets for inflammatory bowel disease.

Authors:  Marjorie Argollo; Gionata Fiorino; Pieter Hindryckx; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  J Autoimmun       Date:  2017-07-12       Impact factor: 7.094

2.  Selected azaphenothiazines inhibit delayed type hypersensitivity and carrageenan reaction in mice.

Authors:  Jolanta Artym; Iwona E Kochanowska; Maja Kocięba; Ewa Zaczyńska; Michał Zimecki; Małgorzata Jeleń; Beata Morak-Młodawska; Krystian Pluta
Journal:  Int Immunopharmacol       Date:  2016-09-12       Impact factor: 4.932

3.  Topically applied azaphenothiazines inhibit contact sensitivity to oxazolone in mice.

Authors:  Jolanta Artym; Maja Kocięba; Ewa Zaczyńska; Michał Zimecki; Małgorzata Jeleń; Beata Morak-Młodawska; Krystian Pluta; Katarzyna Kaleta-Kuratewicz; Jan P Madej; Piotr Kuropka; Jan Kuryszko
Journal:  Histol Histopathol       Date:  2017-07-27       Impact factor: 2.303

Review 4.  A comprehensive review and update on Crohn's disease.

Authors:  Mahesh Gajendran; Priyadarshini Loganathan; Anthony P Catinella; Jana G Hashash
Journal:  Dis Mon       Date:  2017-08-18       Impact factor: 3.800

5.  Dimethyl sulfoxide inhibits NLRP3 inflammasome activation.

Authors:  Huijeong Ahn; Jeeyoung Kim; Eui-Bae Jeung; Geun-Shik Lee
Journal:  Immunobiology       Date:  2013-11-22       Impact factor: 3.144

6.  Topically applied azaphenothiazines inhibit experimental psoriasis in mice.

Authors:  Jolanta Artym; Maja Kocięba; Ewa Zaczyńska; Iwona Kochanowska; Michał Zimecki; Wojciech Kałas; Anna Fiedorowicz; Alicja Pawlak; Leon Strządała; Małgorzata Jeleń; Beata Morak-Młodawska; Krystian Pluta; Katarzyna Kaleta-Kuratewicz; Jan P Madej; Piotr Kuropka; Jan Kuryszko
Journal:  Int Immunopharmacol       Date:  2018-04-16       Impact factor: 4.932

7.  Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis.

Authors:  F Casellas; M Papo; F Guarner; M Antolín; J R Armengol; J R Malagelada
Journal:  Clin Sci (Lond)       Date:  1994-10       Impact factor: 6.124

8.  Dextran sulfate sodium-induced colitis generates a transient thymic involution--impact on thymocyte subsets.

Authors:  M Fritsch Fredin; K Elgbratt; D Svensson; L Jansson; S Melgar; E Hultgren Hörnquist
Journal:  Scand J Immunol       Date:  2007-05       Impact factor: 3.487

9.  Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice.

Authors:  L A Dieleman; B U Ridwan; G S Tennyson; K W Beagley; R P Bucy; C O Elson
Journal:  Gastroenterology       Date:  1994-12       Impact factor: 22.682

Review 10.  Ulcerative colitis and its treatment.

Authors:  A I Jacknowitz
Journal:  Am J Hosp Pharm       Date:  1980-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.